NASDAQ:NBRVNabriva Therapeutics Stock Price, Forecast & News

Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NBRV shares have decreased by 34.5% and is now trading at $0.7930. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Nabriva Therapeutics.

Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Nabriva Therapeutics.

Nabriva Therapeutics PLC - (NASDAQ:NBRV) announced its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.02. The biotechnology company had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.39 million. Nabriva Therapeutics had a negative net margin of 1,001.59% and a negative return on equity of 238.67%. View Nabriva Therapeutics' earnings history.

6 brokerages have issued 1 year price objectives for Nabriva Therapeutics' shares. Their forecasts range from $1.00 to $7.00. On average, they expect Nabriva Therapeutics' stock price to reach $3.92 in the next year. This suggests a possible upside of 393.9% from the stock's current price. View analysts' price targets for Nabriva Therapeutics.

News coverage about NBRV stock has trended positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Nabriva Therapeutics earned a news impact score of 3.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutNabriva Therapeutics.

Some companies that are related to Nabriva Therapeutics include Uniqure (QURE), Axsome Therapeutics (AXSM), Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), Insmed (INSM), Amarin (AMRN), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Intercept Pharmaceuticals (ICPT), Apellis Pharmaceuticals (APLS), Ra Pharmaceuticals (RARX), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), TG Therapeutics (TGTX) and Pacira Biosciences (PCRX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include Agile Therapeutics (AGRX), SCYNEXIS (SCYX), AcelRx Pharmaceuticals (ACRX), Crispr Therapeutics (CRSP), Dynavax Technologies (DVAX), Melinta Therapeutics (MLNT), VBI Vaccines (VBIV), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and Advanced Micro Devices (AMD).

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Nabriva Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (0.18%), Rock Springs Capital Management LP (0.11%), Sabby Management LLC (0.04%), Morgan Stanley (0.04%), Wells Fargo & Company MN (0.01%) and Exane Derivatives (0.01%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Steven P Gelone and Theodore R Schroeder. View institutional ownership trends for Nabriva Therapeutics.

NBRV stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Sabby Management LLC, and Morgan Stanley. Company insiders that have sold Nabriva Therapeutics company stock in the last year include Colin Md Broom, Gary Sender, and Steven P Gelone. View insider buying and selling activity for Nabriva Therapeutics.

NBRV stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Exane Derivatives, and Wells Fargo & Company MN. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Jennifer Schranz, and Theodore R Schroeder. View insider buying and selling activity for Nabriva Therapeutics.

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NBRV stock can currently be purchased for approximately $0.79.

Nabriva Therapeutics has a market capitalization of $750.36 million and generates $9.48 million in revenue each year. The biotechnology company earns $-82,760,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Nabriva Therapeutics employs 162 workers across the globe.

The official website for Nabriva Therapeutics is www.nabriva.com.

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN 1 L2, 19406. The biotechnology company can be reached via phone at 353-1649-2000 or via email at [email protected]